We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Laxai Life Sciences

News List

CSIR, Laxai Life Sciences get DCGI nod for clinical trials of Colchicine on COVID-19 patients expresspharma
June 15, 2021
Enrolment of patients has already begun at multiple sites across India and the trial is likely to be completed in the next 8-10 weeks.
CSIR and Laxai Life Sciences begin phase II trial of niclosamide drug to treat COVID-19 expresspharma
June 08, 2021
Niclosamide has been extensively used in the past for treating tapeworm infection in adults as well as children.
CSIR seeks regulatory nod for clinical trials using combination of antivirals and HDTs against COVID-19 expresspharma
July 08, 2020
It is to determine safety and efficacy of three combination drugs (Favipiravir+Colchicine, Umifenovir+Colchicine and Nafamostat+5-ALA) and a control arm with the standard of care in COVID-19 patients.
A2A Pharmaceuticals Collaborates with Laxai Life Sciences contractpharma
June 10, 2020
Will co-develop SARS-CoV-2 main proteases inhibitors for the treatment of COVID-19.